Lidocaine—A Promising Candidate for the Treatment of Cancer-Induced Bone Pain: A Narrative Review

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-04-15 DOI:10.1007/s12325-025-03192-w

Lihan Luo, Yuqi Cheng, Hanxi Wang, Li Li, Hanyun Niu, Yuzhu Yang, Qianqian Zhou, Jiannan He, Jianhong Xu

引用次数: 0

Abstract

Pain is one of the most common symptoms in patients with cancer, with cancer-induced bone pain (CIBP) significantly affecting their quality of life. Opioids are commonly used as first-line treatments for cancer pain, but their use requires caution due to non-mechanistic analgesia and significant side effects. As a result, there is a need for new non-opioid drugs that target cancer pain through specific mechanisms. Recent studies on the anticancer effects of lidocaine have highlighted its potential benefits in both treating cancer and alleviating cancer-induced pain. This article discusses the mechanism of action and clinical applications of lidocaine in cancer pain management, and suggests new treatment approaches for patients with CIBP.

查看原文本刊更多论文

利多卡因——一种治疗癌症性骨痛的有希望的候选药物：叙述性综述。

疼痛是癌症患者最常见的症状之一，癌性骨痛（CIBP）显著影响患者的生活质量。阿片类药物通常被用作癌症疼痛的一线治疗方法，但由于其非机械性镇痛和显著的副作用，需要谨慎使用。因此，需要通过特定机制靶向癌症疼痛的新型非阿片类药物。最近关于利多卡因抗癌作用的研究强调了它在治疗癌症和减轻癌症引起的疼痛方面的潜在益处。本文就利多卡因在癌性疼痛治疗中的作用机制及临床应用进行了探讨，并提出了治疗CIBP的新途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.